Bulletin of Experimental Biology and Medicine

, Volume 165, Issue 3, pp 382–385 | Cite as

Specific Features of Transcription Activity of Cancer-Testis Antigens in Patients with Metastatic and Non-Metastatic Breast Cancer

  • D. I. Vodolazhsky
  • D. S. KutilinEmail author
  • Kh. A. Mogushkova
  • O. I. Kit

Cancer-testis antigens, effective markers of tissue malignant transformation, are characterized by heterogonous transcription depending on the pathological features of breast cancer. We performed screening of transcription profile of cancer-testis antigens specific for breast tumor tissues in female patients with and without regional metastasis. The relative expression of 16 genes (MAGEA1, MAGEA2, MAGEA3, MAGEA4, MAGEB1, MAGEB2, GAGE1, GAGE3, GAGE4, MAGEC1, BAGE, XAGE3, NY-ESO1, SSX2, SYCP1, and PRAME1) was analyzed by RT-qPCR method in biopsy specimens of the mammary gland tissues obtained during surgery from 25 patients. Differential transcription activity of cancer-testis antigens genes was observed in patients with metastatic (enhanced expression of MAGEA2, MAGEB1, and XAGE3 genes) and non-metastatic (enhanced expression of GAGE3 and PRAME1 genes) breast cancer.

Key Words

gene expression real-time PCR cancer-testis antigens breast cancer metastases 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Vodolazhsky DI, Kutilin DS, Mogushkova KA, Vashchenko LN, Nikitina VP, Kit OI. Transcriptional activity of cancer-testis antigens in patients with breast cancer of luminal subtypes A and B. Sovremen. Probl. Nauki Obrazovaniya. 2017;(4):5. Russian.Google Scholar
  2. 2.
    Kutilin DS, Dimitriadi SN, Vodolazhsky DI, Frantsiyants HM, Kit OI. Effect of thermal ischemia-reperfusion on expression of apoptosis-regulating genes in the renal tissue of patients with renal cell carcinoma. Nefrologiya. 2017;21(1):80-86. Russian.Google Scholar
  3. 3.
    Pak DD, Usov FN, Fetisova EYu, Volchenko AA, Efanov VV. Modern approaches to the treatment of patients with in situ breast carcinoma. Onkologiya. 2013;1(4):30-33. Russian.Google Scholar
  4. 4.
    Przhedetskii YuV, Vodolazhsky DI, Shatova Yu, Komova EA, Dvadnenko KV. BRCA mutations in patients with clinical signs of hereditary breast cancer in the Southern Federal district. Zlokach. Opukholi. 2015;(S2):196-197. Russian.Google Scholar
  5. 5.
    Ahmad A. Pathways to breast cancer recurrence. ISRN Oncol. 2013;2013. ID 290568. doi:
  6. 6.
    Aoki M, Ueda S, Nishikawa H, Kitano S, Hirayama M, Ikeda H, Toyoda H, Tanaka K, Kanai M, Takabayashi A, Imai H, Shiraishi T, Sato E, Wada H, Nakayama E, Takei Y, Katayama N, Shiku H, Kageyama S. Antibody responses against NY-ESO-1 and HER2 antigens in patients vaccinated with combinations of cholesteryl pullulan (CHP)-NY-ESO-1 and CHP-HER2 with OK-432. Vaccine. 2009;27(49):6854-6861.CrossRefPubMedGoogle Scholar
  7. 7.
    Chomczynski P, Sacchi N. The single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction: twenty-something years on. Nat. Protoc. 2006;1(2):581-585.CrossRefPubMedGoogle Scholar
  8. 8.
    Grigoriadis A, Caballero OL, Hoek KS, da Silva L, Chen YT, Shin SJ, Jungbluth AA, Miller LD, Clouston D, Cebon J, Old LJ, Lakhani SR, Simpson AJ, Neville AM. CT-X antigen expression in human breast cancer. Proc. Natl Acad. Sci. USA. 2009;106(32):13,493-13,498.CrossRefGoogle Scholar
  9. 9.
    Kavalar R, Sarcevic B, Spagnoli G.C, Separovic V, Samija M, Terracciano L, Heberer M, Juretic A. Expression of MAGE tumour-associated antigens is inversely correlated with tumour differentiation in invasive ductal breast cancers: an immunohistochemical study. Virchows Arch. 2001;439(2):127-131.CrossRefPubMedGoogle Scholar
  10. 10.
    Krüger S, Ola V, Feller A.C, Fischer D, Friedrich M. Expression of cancer-testis antigen CT7 (MAGE-C1) in breast cancer: an immunohistochemical study with emphasis on prognostic utility. Pathol. Oncol. Res. 2007;13(2):91-96.CrossRefPubMedGoogle Scholar
  11. 11.
    Lian Y, Sang M, Ding C, Zhou X, Fan X, Xu Y, Lü W, Shan B. Expressions of MAGE-A10 and MAGE-A11 in breast cancers and their prognostic significance: a retrospective clinical study. J. Cancer Res. Clin. Oncol. 2012;138(3):519-527.CrossRefPubMedGoogle Scholar
  12. 12.
    Matković B, Juretić A, Spagnoli G.C, Separović V, Gamulin M, Separović R, Sarić N, Basić-Koretić M, Novosel I, Kruslin B. Expression of MAGE-A and NY-ESO-1 cancer/testis antigens in medullary breast cancer: retrospective immunohistochemical study. Croat. Med. J. 2011;52(2):171-177.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat. Protoc. 2008;3(6):1101-1108.CrossRefPubMedGoogle Scholar
  14. 14.
    Theurillat JP, Ingold F, Frei C, Zippelius A, Varga Z, Seifert B, Chen YT, Jäger D, Knuth A, Moch H. NY-ESO-1 protein expression in primary breast carcinoma and metastases: correlation with CD8+ T-cell and CD79a+ plasmacytic/B-cell infiltration. Int. J. Cancer. 2007;120(11):2411-2417.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • D. I. Vodolazhsky
    • 1
  • D. S. Kutilin
    • 1
    Email author
  • Kh. A. Mogushkova
    • 1
  • O. I. Kit
    • 1
  1. 1.Rostov Research Institute of OncologyMinistry of Health of the Russian FederationRostov-on-DonRussia

Personalised recommendations